Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …